News
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=us)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
![Is CRISPR Therapeutics Stock a Buy Now?: https://g.foolcdn.com/editorial/images/736895/gettyimages-1096502340.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMU0yYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--76070af6088685011d8669b9d452c64cbce85e31/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1096502340.jpg?locale=us)
Is CRISPR Therapeutics Stock a Buy Now?
An important moment may be only a few months away for CRISPR Therapeutics (NASDAQ: CRSP). I'm talking about the potential approval of its very first product. The U.S. Food and Drug Administration
![Why Shares of Vera Therapeutics Jumped Tuesday: https://g.foolcdn.com/editorial/images/736985/radiologist-of-oncology-institute-is-examing-mri-scans.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeWsyYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--cc35a5f92766b15851792a411ac4d6a1882cab5a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/radiologist-of-oncology-institute-is-examing-mri-scans.jpg?locale=us)
Why Shares of Vera Therapeutics Jumped Tuesday
Shares of Vera Therapeutics (NASDAQ: VERA) closed 16.9% higher on Tuesday after jumping as much as 23.5%. The clinical-stage biotech company announced positive news regarding trial results for one
![Why Quotient Technology Stock Was Up on Tuesday: https://g.foolcdn.com/editorial/images/736914/online-shopping-with-credit-card-at-home.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNlUxYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3891a7dcbc6a61976d81603ebfb94c6b04d7ad19/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/online-shopping-with-credit-card-at-home.jpg?locale=us)
Why Quotient Technology Stock Was Up on Tuesday
Quotient Technology (NYSE: QUOT) shareholders had a great to start to the trading week. The digital promotions and media tech specialist's stock jumped 16% in early trading, compared to a nearly 1%
![Better Buy: AT&T vs. Amazon: https://g.foolcdn.com/editorial/images/736707/family-piggy-bank.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNmMxYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fd2f3f511b86be1494aa73062a2ba43f7aa5f88c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/family-piggy-bank.jpg?locale=us)
Better Buy: AT&T vs. Amazon
AT&T (NYSE: T) and Amazon (NASDAQ: AMZN) are both often considered stable long-term investments. AT&T is one of the largest telecom companies in the United States, and it has paid continuous
![After Blasting Off 881% in 1 Year, Is Viking Therapeutics Still a Good Buy?: https://g.foolcdn.com/editorial/images/736473/scientists-lab-testing-vaccine-development1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMzgxYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e49a6513ac7e2df4650269e0b362f3d37c183027/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-lab-testing-vaccine-development1.jpg?locale=us)
After Blasting Off 881% in 1 Year, Is Viking Therapeutics Still a Good Buy?
Viking Therapeutics (NASDAQ: VKTX) is up 881% in the last 12 months thanks to its ongoing development of a pair of therapies to treat obesity and metabolic disorders like diabetes. As you may have
![EQS-News: Evotec SE Annual General Meeting 2023 approves all proposed agenda items: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBMUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--5ccaaee20e4dd47dccd2b888e74ce998199f16f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Evotec_high_res_logo_-28blue_and_grey-29.jpg?locale=us)
EQS-News: Evotec SE Annual General Meeting 2023 approves all proposed agenda items
![Where Will Axsome Therapeutics Be in 3 Years?: https://g.foolcdn.com/editorial/images/736806/gettyimages-1147525564.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeTgxYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2b4df45a23f85f0193aef1e701f5bb98e90521f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1147525564.jpg?locale=us)
Where Will Axsome Therapeutics Be in 3 Years?
Last year was a big one for Axsome Therapeutics (NASDAQ: AXSM). The biotech company specialized in central nervous system conditions launched its first two products and saw its share price increase
![Best Dividend Stock to Buy: AT&T vs. Deere: https://g.foolcdn.com/editorial/images/736838/untitled-design-32.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKzAwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--635939a584b2637d085138d835530dc9a8518442/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/untitled-design-32.png?locale=us)
Best Dividend Stock to Buy: AT&T vs. Deere
Fool.com contributor and finance professor Parkev Tatevosian compares AT&T (NYSE: T) and Deere (NYSE: DE) to determine which is the better dividend stock to buy.
*Stock prices used were the
![Illumina's CEO Was Just Ousted: Should Investors Buy In Now or Steer Clear?: https://g.foolcdn.com/editorial/images/736470/3-worried-investors-talk-at-a-table.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNmMwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ec1b806b8f3c8ba959d0331d8584e9eda5ea8ff0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/3-worried-investors-talk-at-a-table.jpg?locale=us)
Illumina's CEO Was Just Ousted: Should Investors Buy In Now or Steer Clear?
On June 11, the gene sequencing giant Illumina (NASDAQ: ILMN) announced that its CEO, Francis deSouza, resigned after a tenure of roughly 10 years and that the company would start looking for a
![What Do Bears Know About Novavax That Bulls Don't?: https://g.foolcdn.com/editorial/images/736798/gettyimages-healthcare-worker-prepares-vaccine-dose.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNncwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5967784116787be0d949edaeb18056bc7b9d9d25/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-healthcare-worker-prepares-vaccine-dose.jpg?locale=us)
What Do Bears Know About Novavax That Bulls Don't?
Novavax (NASDAQ: NVAX) soared early in the coronavirus vaccine race. The stock climbed more than 2,700% in 2020.
But as the biotech company fell behind in the race, so did its shares. Novavax
![If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position: https://g.foolcdn.com/editorial/images/736546/healthcare-lab-treatment-research-scientist-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNjAwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--565224ccb7a802ee4bee0b2797f05b348dec5bd0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/healthcare-lab-treatment-research-scientist-1.jpg?locale=us)
If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position
Nano-X Imaging (NASDAQ: NNOX), DermTech (NASDAQ: DMTK), and Viking Therapeutics (NASDAQ: VKTX) are healthcare growth stocks with plenty of potential, little revenue, and a boatload of risk.
Share
![Why Investors Should Care About Novartis' Latest Label Expansion -- It Could Mean Billions: https://g.foolcdn.com/editorial/images/736519/a-customer-shops-at-a-pharmacy.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMDgwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae19a7f2340b90932e7519809b00477f7de74c07/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-customer-shops-at-a-pharmacy.jpg?locale=us)
Why Investors Should Care About Novartis' Latest Label Expansion -- It Could Mean Billions
Earlier this month, Novartis' (NYSE: NVS) smash-hit immunology medicine Cosentyx became the first drug within its class to be approved in the European Union to treat adult patients with moderate to
![Intellia Therapeutics Stock Could Roar in the Next Bull Market. Here's Why.: https://g.foolcdn.com/editorial/images/736480/scientists-lab-testing-blood-draw1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMUkwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d4e787166626a1144346a9a56a6ec81a423f00c2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-lab-testing-blood-draw1.jpg?locale=us)
Intellia Therapeutics Stock Could Roar in the Next Bull Market. Here's Why.
Even after rising 30% so far this year, shares of Intellia Therapeutics (NASDAQ: NTLA) could easily experience another leg up if there's a bull market in the latter half of 2023. With positive
![2 Promising Stocks That Are Screaming Buys in June: https://g.foolcdn.com/editorial/images/736431/a-person-looking-at-a-computer.jpeg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeWMwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d63465ebf7b768e4e002f3f66078fc50ce72273c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-person-looking-at-a-computer.jpg?locale=us)
2 Promising Stocks That Are Screaming Buys in June
While 2022 was disastrous for much of the market, 2023 is shaping up to be much better, with the S&P 500 already up nearly 15% so far this year. Long-term investors understand that these ups and
![2 Beaten-Down Dividend Growth Stocks to Buy on the Dip: https://g.foolcdn.com/editorial/images/736469/a-couple-investing-getty.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeGMwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ecc000c6e1cd87fc1addb605f03d4387e92cdc44/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-couple-investing-getty.jpg?locale=us)
2 Beaten-Down Dividend Growth Stocks to Buy on the Dip
Shares of health insurance benefits managers dropped last Wednesday after the largest member of their industry, UnitedHealth Group (NYSE: UNH), issued a minor warning. Speaking at an investor
![Does This Signal Trouble for Biogen's New Alzheimer's Drug?: https://g.foolcdn.com/editorial/images/736443/gettyimages-pensive-investor-at-computer.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdzAwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--da31b0793533e7d6ad2a5ccb7ed2107c16775b7e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-pensive-investor-at-computer.jpg?locale=us)
Does This Signal Trouble for Biogen's New Alzheimer's Drug?
Biogen (NASDAQ: BIIB) recently got some good news in the U.S. An advisory committee for the Food and Drug Administration (FDA) unanimously confirmed the clinical benefit of its Alzheimer's drug
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=us)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
![Nvidia Is About to Change Gaming Forever With AI: https://g.foolcdn.com/editorial/images/736434/ai-software.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOUF6YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--60a371cd59e4777411b3a5a33bb3c01dbf87c140/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ai-software.jpg?locale=us)
Nvidia Is About to Change Gaming Forever With AI
Nvidia's (NASDAQ: NVDA) explosive growth in its data center segment recently overtook gaming as the company's largest source of revenue. But gaming is still a large business, generating a third of
![2 Market-Beating Stocks With Major Catalysts on the Way: https://g.foolcdn.com/editorial/images/736385/physician-giving-medicine-to-elderly-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNWd6YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7c49e5ae20e5dfe7022c0e4e3f850a8821ca5d16/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physician-giving-medicine-to-elderly-patient.jpg?locale=us)
2 Market-Beating Stocks With Major Catalysts on the Way
For those seeking stocks that have trounced the market over the past year, the biotech sector might be an excellent place to start. The SPDR S&P Biotech Index ETF, an industry benchmark, has climbed
![3 Cathie Wood Investments That Could Deliver Superior Returns: https://g.foolcdn.com/editorial/images/736111/dna-genetic-sequencing-biotech-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNU16YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8873c710dd721cf2710f4f95e887eca359fc8903/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/dna-genetic-sequencing-biotech-1.jpg?locale=us)
3 Cathie Wood Investments That Could Deliver Superior Returns
Cathie Wood, the CEO of Ark Investment, has made a name for herself by betting on cutting-edge technology with financial technology stocks, or fintechs, and biotechnology growth stocks making up a
![Could Viking Therapeutics Stock Help You Become a Millionaire?: https://g.foolcdn.com/editorial/images/736139/a-team-of-scientists-reviewing-results-in-a-lab.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNVF6YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8740b009abcdec2017ba97eeb976dd9c8f590b5a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-team-of-scientists-reviewing-results-in-a-lab.jpg?locale=us)
Could Viking Therapeutics Stock Help You Become a Millionaire?
An up-and-coming stock with lots of potential is Viking Therapeutics (NASDAQ: VKTX). Investors have been piling money into the biotech stock this year, as it has surged 150% since January. And at a
![3 Bargain Stocks to Buy on the Dip: https://g.foolcdn.com/editorial/images/736534/stock-chart-trending-down-with-man.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM1V6YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--24dec8e78def0b7fdd02d35ee7350b6047fee67b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/stock-chart-trending-down-with-man.jpg?locale=us)
3 Bargain Stocks to Buy on the Dip
Buy on the dip. Most investors have heard the old saying. However, it's only good advice when a stock is likely to rebound strongly.
Three Motley Fool contributors think they've identified stocks
![Does an $11.5 Billion Opportunity Make This Growth Stock a Buy Now?: https://g.foolcdn.com/editorial/images/736432/a-person-delivering-a-presentation-getty.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMnd6YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3249d783f145522e24b2f1bfd518c50abe5ab943/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-person-delivering-a-presentation-getty.jpg?locale=us)
Does an $11.5 Billion Opportunity Make This Growth Stock a Buy Now?
Axsome Therapeutics (NASDAQ: AXSM) stock jumped more than 10% on June 14 after the company made its latest investor presentation public. The market was reacting to new estimates that suggest peak